Andrew Callos Cytokinetics Inc (CYTK) insider trading activity

Andrew Callos is EVP, Chief Commercial Officer of CYTOKINETICS INC. Currently has a direct ownership of 60,687 shares of CYTK, which is worth approximately $1.98 Million. The most recent transaction as insider was on May 05, 2025, when has been sold 4,002 shares (Common Stock) at a price of $36.68 per share, resulting in proceeds of $146,793. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 60.7K

7.65% 3M change

5.01% 12M change

Total Value Held $1.98 Million

Andrew Callos Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 05 2025	SELL Open market or private sale	$146,793 $36.68 p/Share	4,002 Reduced 6.19%	60,687 Common Stock
Apr 07 2025	SELL Open market or private sale	$103,261 $35.78 p/Share	2,886 Reduced 4.27%	64,689 Common Stock
Mar 17 2025	SELL Open market or private sale	$123,154 $44.38 p/Share	2,775 Reduced 7.37%	34,888 Common Stock
Mar 17 2025	SELL Open market or private sale	$943,426 $45.14 p/Share	20,900 Reduced 35.69%	37,663 Common Stock
Mar 17 2025	BUY Exercise of conversion of derivative security	$486,134 $23.26 p/Share	20,900 Added 26.3%	58,563 Common Stock
Mar 14 2025	SELL Open market or private sale	$4,500 $45.0 p/Share	100 Reduced 0.26%	37,663 Common Stock
Mar 14 2025	BUY Grant, award, or other acquisition	-	32,687 Added 31.72%	70,350 Common Stock
Mar 14 2025	BUY Exercise of conversion of derivative security	$2,326 $23.26 p/Share	100 Added 0.26%	37,763 Common Stock
Mar 13 2025	SELL Open market or private sale	$1,167,751 $43.62 p/Share	26,771 Reduced 41.55%	37,663 Common Stock
Mar 06 2025	SELL Open market or private sale	$144,565 $43.27 p/Share	3,341 Reduced 4.93%	64,434 Common Stock
Mar 03 2025	SELL Open market or private sale	$47,768 $42.88 p/Share	1,114 Reduced 1.62%	67,775 Common Stock
Dec 03 2024	SELL Payment of exercise price or tax liability	$69,590 $51.51 p/Share	1,351 Reduced 2.01%	65,712 Common Stock
Dec 03 2024	BUY Grant, award, or other acquisition	-	6,353 Added 8.44%	68,889 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	16,941 Added 20.96%	63,887 Common Stock
Mar 06 2024	SELL Payment of exercise price or tax liability	$341,288 $66.88 p/Share	5,103 Reduced 9.8%	46,946 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$149,031 $67.68 p/Share	2,202 Reduced 4.06%	52,049 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	30,000 Added 35.85%	53,683 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$87,199 $39.6 p/Share	2,202 Reduced 8.51%	23,683 Common Stock
Feb 16 2023	SELL Payment of exercise price or tax liability	$42,761 $44.13 p/Share	969 Reduced 3.61%	25,885 Common Stock
Mar 02 2022	BUY Grant, award, or other acquisition	-	20,000 Added 43.29%	26,196 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	5,044 Added 44.88%	6,196 Common Stock

Andrew Callos

EVP, Chief Commercial Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account